Holen Sie sich die Stockscreener-App
3.97
0.25%
-0.010
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Comparing VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI) - Defense World
Senti Biosciences (NASDAQ:SNTI) & BioNTech (NASDAQ:BNTX) Head to Head Review - Defense World
Senti Bio Launches Groundbreaking CAR-NK Cell Therapy Trial for Liver Cancer in China - StockTitan
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences By Investing.com - Investing.com Nigeria
Cathie Wood's ARK buys Tempus AI stock, sheds Senti Biosciences - Investing.com
Chardan Capital Has Negative Outlook of SNTI FY2024 Earnings - Defense World
Senti Bio price target raised to $12 from $10 at Chardan - Yahoo Finance
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed - MSN
Chardan lifts Senti Biosciences stock target on positive trial data By Investing.com - Investing.com Nigeria
Chardan lifts Senti Biosciences stock target on positive trial data - Investing.com
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Senti Biosciences Approves New Employee Stock Options in Latest Inducement Grants - StockTitan
Stock market news: Sharps Technology -34.40%, Senti Biosciences -28.60% among biggest losers during mid day trading - Business Upturn
Stock market news: Exicure -34.53%, Senti Biosciences -23.70% among biggest losers in early trading - Business Upturn
Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202 - Yahoo Finance
Senti Biosciences reports early success in AML trial - The Pharma Letter
Senti Bio appoints new board member and audit chair By Investing.com - Investing.com Canada
Senti Biosciences, Inc. announced that it expects to receive $37.60425 million in funding from Celadon Partners, New Enterprise Associates, Inc., Leaps by Bayer, Nantahala Capital Management, LLC and other investors - Marketscreener.com
Senti Biosciences, Inc. (SNTI) could keep surging and here’s why - BP Journal
Senti Biosciences Advances with Key Financial and Strategic Moves - TipRanks
Stock market news: Senti Biosciences +404.62%, Fossil Group +54.11% among top gainers during mid day trading - Business Upturn
Stock market news: Intel rises 4%,Apple increases 1.08%,Super Micro Computer surges 32.31% - Business Upturn
Stock market news: Senti Biosciences surge by 428.24% while Mondee Holdings plunged by 46.49% during mid day trading - Business Upturn
Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Inkl
Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial - MarketWatch
Stock market today: Senti Biosciences +412.04%, NovoCure +31.89% among top gainers in early trading - Business Upturn
Stock market today: Senti Biosciences surged 344.42% while Mondee Holdings declined by 31.33% in early trading - Business Upturn
SNTI Stock Soars to 52-Week High, Reaching $7.7 - Investing.com
Senti Biosciences stock soars 200% on positive trial data By Investing.com - Investing.com Nigeria
SNTI Stock Soars to 52-Week High, Reaching $7.7 By Investing.com - Investing.com UK
Senti Biosciences stock soars 200% on positive trial data - Investing.com
U.S. STOCKS Intel, PTC Therapeutics, Senti Bio - XM
Senti Biosciences’ SENTI-202 Shows Promising Phase 1 Results - TipRanks
Senti Bio announces oversubscribed $37.6M private placement financing - TipRanks
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - The Manila Times
Senti Bio appoints Fran Schulz to board of directors - TipRanks
Senti Bio appoints new board member and audit chair - Investing.com
Senti Bio Appoints Fran Schulz to Board of Directors - The Manila Times
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - The Manila Times
Senti Biosciences Secures $37.6M Private Placement for Cancer Therapy Development - StockTitan
Senti Bio Appoints Life Sciences Finance Veteran Fran Schulz to Board, Names Audit Chair - StockTitan
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Senti Biosciences Faces Financial Challenges Amid Strategic Focus - TipRanks
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - The Manila Times
Senti Biosciences Inc (SNTI) Quarterly 10-Q Report - Quartzy
Senti Bio Reports $28.9M Q3 Loss, Advances Cancer Drug Trial Amid Cost Cuts | SNTI Stock News - StockTitan
Intel says it lowered stakes in Astera Labs, Joby Aviation, Senti Biosciences - MSN
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Palantir Technologies Inc (PLTR-Q) QuotePress Release - The Globe and Mail
Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update - MarketBeat
Senti Biosciences faces nasdaq delisting over audit rule By Investing.com - Investing.com Australia
Senti Biosciences faces nasdaq delisting over audit rule - Investing.com India
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):